Intercure (INCR) vs Medicinova (MNOV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Medicinova (MNOV) has outperformed Intercure (INCR) over the past year, gaining 26.2% versus a loss of 38.5%. Over five years, MNOV leads with a -59.7% price change compared with -85.4% for INCR. Intercure is the larger company by market cap ($77.6 million vs $74.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INCR | MNOV |
|---|---|---|
| Share price | $5.17 | $1.52 |
| Market cap | $77.57M | $74.82M |
| 1-day change | +2.99% | -1.30% |
| YTD return | +13.63% | +17.56% |
| 1-year return | -38.45% | +26.23% |
| 5-year return | -85.42% | -59.69% |
| EPS (TTM) | $-0.95 | $-0.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.32 | $3.90 |
| 52-week low | $3.40 | $1.17 |
| Distance from 52-week high | -37.86% | -61.03% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +442.76% |
| Average volume | 22.06K | 327.41K |
| Shares outstanding | 15.00M | 49.22M |
| Employees | 285 | 6 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MNOV has outperformed INCR by 64.7 percentage points over the past year.
About Intercure
INCR stock →InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.
Health Care · Biotechnology: Pharmaceutical Preparations · 285 employees
About Medicinova
MNOV stock →MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
INCR vs MNOV FAQ
Which is bigger, Intercure or Medicinova?
Intercure (INCR) is larger, with a market capitalization of $77.57M compared with $74.82M for Medicinova (MNOV).
Which stock has performed better over the past year, INCR or MNOV?
MNOV returned +26.23% over the past 12 months, compared with -38.45% for INCR (price return, excluding dividends). Past performance does not predict future results.
Are Intercure and Medicinova in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.